BCMA targeted CAR T

P1, N=19, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy

P1, N=19, Active, not recruiting, Fred Hutchinson Cancer Center | Suspended --> Active, not recruiting

CMV testing could be considered between 2-6 weeks in high-risk CARTx-recipients.

P1, N=18, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2025

P1, N=18, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Apr 2022 --> Sep 2025 | Trial primary completion date: Apr 2022 --> Sep 2024

Clinical trials have shown that BCMA targeted CAR-T therapy induces MM remission in most patients with heavily pretreated relapsed refractory MM; however, the duration of the response has been disappointing...This suggests that soluble factors in the BMM can convert cells from type I to type II (mitochondrial-dependent) death receptor signaling and that inhibiting BMM signals such as IL6 may enhance FASL-induced cell death in MM. However, the data also demonstrate that the role of FAS in CAR-T killing is cell context dependent.

We have completed accrual to a phase 1 first-in-human trial of escalating doses of BCMA targeted CAR T cells in combination with a GSI (JSMD194) for patients with relapsed or refractory multiple myeloma, and herein report results on the 18 patients accrued to this trial. From June 2018 to March 2021, 18 patients underwent leukapheresis, run-in with JSMD194, and treatment with BCMA CAR T cells. The median age was 65 years, and patients had received a median of 10 prior lines of therapy (range, 4-19). 67% of patients were refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, 72% had high-risk cytogenetic features, and 28% had extramedullary disease.